Company intelligence / Profile preview
Peptide Logic
San Diego, California, United Statespeptidelogic.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Peptide Logic develops novel peptide-antibody conjugates to address pain and opioid addiction. Their approach combines synthetic peptides with recombinant antibodies to create first-in-class therapeutics that are non-addictive, peripherally restricted, and long acting. The company has a focus on reducing prescription opioid use and preventing addiction but does not currently have any programs in clinical trials according to public registries.
- Therapeutic areas
- OtherPsychiatryNeurology
- Modalities
- Synthetic peptidesRecombinant antibodies (peptide-antibody conjugates / PACs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
National Institutes of Health (NIH) – investor/grant supportJLabs – investor/incubator partner
Beyond the preview
Go deeper on Peptide Logic.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptide Logic.